FORA Capital LLC Takes Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

FORA Capital LLC acquired a new stake in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 24,004 shares of the life sciences company's stock, valued at approximately $436,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Blue Trust Inc. increased its stake in shares of Integra LifeSciences by 100.5% in the 2nd quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock worth $26,000 after acquiring an additional 444 shares during the last quarter. CWM LLC increased its stake in shares of Integra LifeSciences by 50.8% in the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock worth $37,000 after acquiring an additional 425 shares during the last quarter. KBC Group NV increased its stake in shares of Integra LifeSciences by 65.2% in the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock worth $52,000 after acquiring an additional 1,120 shares during the last quarter. Northwest Investment Counselors LLC acquired a new stake in shares of Integra LifeSciences in the 3rd quarter worth $73,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of Integra LifeSciences during the 2nd quarter worth about $114,000. Hedge funds and other institutional investors own 84.78% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently issued reports on IART. BTIG Research raised Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. Truist Financial cut their price objective on Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research report on Monday, October 14th. Bank of America dropped their target price on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a research report on Monday, October 7th. Finally, Citigroup lifted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the company a "sell" rating in a research report on Tuesday, November 5th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $24.00.

Integra LifeSciences Stock Up 0.2 %

IART stock traded up $0.04 during trading on Friday, hitting $24.58. 249,836 shares of the company's stock were exchanged, compared to its average volume of 1,089,028. The business has a 50-day moving average price of $20.77 and a two-hundred day moving average price of $24.00. The stock has a market capitalization of $1.90 billion, a price-to-earnings ratio of -273.08, a PEG ratio of 0.83 and a beta of 1.08. Integra LifeSciences Holdings Co. has a 52-week low of $16.81 and a 52-week high of $45.42. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.02. The firm had revenue of $380.80 million during the quarter, compared to analysts' expectations of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm's revenue was down .4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.76 earnings per share. As a group, equities research analysts expect that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.